New Treatments (MSC) in Immune Disorders Like Cancers and Covid Infection: Cancer and Virus New Treatment (MSC ) DOI Creative Commons

Nadia Ghasemi Darestani,

Soheyla Hashemi,

Zahra Rahimi

и другие.

Asian Pacific Journal of Cancer Biology, Год журнала: 2024, Номер 9(2), С. 257 - 261

Опубликована: Апрель 15, 2024

The recent coronavirus disease 2019 outbreak and viral infections around the world has had an enormous impact on global health burden, threatening lives of many individuals, spatially with underlying like cancerous patients severe socio-economic consequences. Many pharmaceutical biotechnology companies have commenced intensive research different therapeutic strategies, from repurposed antiviral drugs to vaccines monoclonal antibodies prevent spread treat infected patients. Among various advanced approaches including cell- gene-editing-based therapeutics are also being investigated, initial results in in-vitro early phase I studies been promising. However, further assessments required. This article reviews mechanisms for pathogenesis of, discusses available candidates modalities that evaluated used treatment immune deficient cancers viruses infected.

Язык: Английский

Improving systemic delivery of oncolytic virus by cellular carriers DOI Creative Commons
Ziyi Peng, Muhammad Kalim,

Yong Lu

и другие.

Cancer Biology and Medicine, Год журнала: 2025, Номер 21(12), С. 1104 - 1119

Опубликована: Янв. 17, 2025

Oncolytic virotherapy (OVT) is a promising option for cancer treatment. OVT involves selective oncolytic virus (OV) replication within cells, which triggers anti-tumor responses and immunostimulation. Despite potential, faces critical challenges, including insufficient tumor-specific targeting, results in limited tumor penetration variability therapeutic efficacy. These challenges are particularly pronounced solid tumors with complex microenvironments heterogeneous vascularization. A comprehensive research program currently underway to develop refine innovative delivery methods address these issues enhance precision principal area of investigation the utilization cellular carriers distribution OVs microenvironments, thereby optimizing immune system activation maximizing effects. This review offers overview current strategies that being used via goal improving clinical impact therapy.

Язык: Английский

Процитировано

0
Oncolytic Virus Therapy in a New Era of Immunotherapy, Enhanced by Combination with Existing Anticancer Therapies: Turn up the Heat! DOI Creative Commons

Emily Charlotte Fretwell,

Annwyne Houldsworth

Journal of Cancer, Год журнала: 2025, Номер 16(6), С. 1782 - 1793

Опубликована: Фев. 18, 2025

Oncolytic viral therapy is a promising treatment for cancer, where 'cold' tumour cells can become 'hot' to the host immune system. However, with few FDA approved therapies, development of new strategies more cancer types has been slow and relatively unsuccessful in recent years, Combination successful other treatment, therefore, may be viable alternative improve efficacy oncolytic which reduce some adverse events currently used monotherapies, virus chemotherapy being mutually complimentary each other. Combining viruses checkpoint inhibitors provides significant increase when was combined drug ipilimumab. Phase I II studies concluded that combination chemotherapies safe effective but did not significantly on current monotherapies. Recent experiments suggest CAR-T CAR--M therapeutic approach needs advance clinical testing observe human response therapy. Viral ipilimumab showed highest potential trials should advanced phase III find conclusive supporting evidence. This review aims identify evaluate evolving advances genetic engineering providing enhanced activity tumour, addressing lack responses tumours, an additional role enhancing conventional therapies. The 'turn up heat' microenvironment immunogenicity anticancer treatments, future

Язык: Английский

Процитировано

0
Capsicum in Clinical Biochemistry: Insights into its Role in Health and Disease DOI

Ayman Faris Faisal,

Yasser Fakri Mustafa

Indian Journal of Clinical Biochemistry, Год журнала: 2025, Номер unknown

Опубликована: Март 25, 2025

Язык: Английский

Процитировано

0
Potent antitumor efficacy of human dental pulp stem cells armed with YSCH-01 oncolytic adenovirus DOI Creative Commons

Xu He,

Wei Yao,

Ji-Ding Zhu

и другие.

Journal of Translational Medicine, Год журнала: 2023, Номер 21(1)

Опубликована: Окт. 3, 2023

Abstract Background Systemic administration of oncolytic adenovirus for cancer therapy is still a challenge. Mesenchymal stem cells as cell carriers have gained increasing attention in drug delivery due to their excellent tumor tropism, immunosuppressive modulatory effects, and paracrine effects. However, the potential human dental pulp (hDPSCs) loaded with biotherapy has not been investigated yet. Methods The stemness hDPSCs was characterized by FACS analysis Alizarin red staining, Oil Red O immunofluorescence assays. biological fitness YSCH-01 confirmed virus infection different dosages viability CCK-8 Additionally, expression CAR receptor detected qPCR assay. Tumor tropism hDPSC vitro vivo Transwell assays living tumor-bearing mice imaging technology immunohistochemistry, Panoramic scanning frozen section slices assay analysis. Furthermore, antitumor efficacy observed through routes YSCH-01/hPDSCs SW780 SCC152 xenograft models. direct cell-killing effect YSCH-01/hDPSCs co-culture system studied, supernatant inhibited growth further analyzed Results were found be susceptible novel named capable transporting this sites at 1000 VP/cell infectious dosage vivo. Moreover, it discovered that intraperitoneal injection exhibited anti-tumor effects both crucial role played secretome derived from significantly exerted specific without toxicity normal cells, an active exogenous protein-independent manner. use carrier reduced required compared other methods. Conclusions These findings highlight promising clinical field virus-based anti-cancer therapy.

Язык: Английский

Процитировано

9
Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? DOI Creative Commons

Hongbin Wang,

Mia C. Borlongan, Howard L. Kaufman

и другие.

Journal for ImmunoTherapy of Cancer, Год журнала: 2024, Номер 12(5), С. e008025 - e008025

Опубликована: Май 1, 2024

Cytokines are small proteins that regulate the growth and functional activity of immune cells, several have been approved for cancer therapy. Oncolytic viruses agents mediate antitumor by directly killing tumor cells inducing responses. Talimogene laherparepvec is an oncolytic herpes simplex virus type 1 (oHSV), treatment recurrent melanoma, encodes human cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF). A significant advantage ability to deliver therapeutic payloads site can help drive immunity. While cytokines especially interesting as payloads, optimal cytokine(s) used in remains controversial. In this review, we highlight preliminary data with chemokines, including GM-CSF, interleukin 12, FMS-like tyrosine kinase 3 ligand, necrosis α, 2, 15, 18, chemokine (C-C motif) ligand 5, (C-X-C 4, or their combinations, show how these further enhance immunity oHSV. better understanding cytokine delivery oHSV improve clinical benefit from immunotherapy patients cancer.

Язык: Английский

Процитировано

3
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas DOI
Georgios M. Stergiopoulos, Susanna C. Concilio, Evanthia Galanis

и другие.

Current Treatment Options in Oncology, Год журнала: 2024, Номер 25(7), С. 952 - 991

Опубликована: Июнь 19, 2024

Язык: Английский

Процитировано

3
Novel Pyrimidine-5-Carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFRWT/T790M and PI3k enzymes; Design, Synthesis, biological Evaluation, and docking studies DOI
N. Di Reda, Khaled O. Mohamed, Kareem Abdou

и другие.

Bioorganic Chemistry, Год журнала: 2024, Номер 145, С. 107185 - 107185

Опубликована: Фев. 9, 2024

Язык: Английский

Процитировано

2
Mesenchymal-Stem-Cell-Based Therapy against Gliomas DOI Creative Commons

Sisa M. Santillán-Guaján,

Mehdi Hayat Shahi, Javier S. Castresana

и другие.

Cells, Год журнала: 2024, Номер 13(7), С. 617 - 617

Опубликована: Апрель 2, 2024

Glioblastoma is the most aggressive, malignant, and lethal brain tumor of central nervous system. Its poor prognosis lies in its inefficient response to currently available treatments that consist surgical resection, radiotherapy, chemotherapy. Recently, use mesenchymal stem cells (MSCs) as a possible kind cell therapy against glioblastoma gaining great interest due their immunomodulatory properties, tropism, differentiation into other types. However, MSCs seem present both antitumor pro-tumor properties depending on tissue from which they come. In this work, possibility using deliver therapeutic genes, oncolytic viruses, miRNA presented, well strategies can improve efficacy glioblastoma, such CAR-T cells, nanoparticles, exosomes.

Язык: Английский

Процитировано

2
Mesenchymal stem cells as therapeutic vehicles for glioma DOI
Tomoya Oishi, Shinichiro Koizumi, Kazuhiko Kurozumi

и другие.

Cancer Gene Therapy, Год журнала: 2024, Номер 31(9), С. 1306 - 1314

Опубликована: Апрель 23, 2024

Язык: Английский

Процитировано

2
Syngeneic mesenchymal stem cells loaded with telomerase-dependent oncolytic adenoviruses enhance anti-metastatic efficacy DOI Creative Commons

Mei-Lin Yang,

Che‐Yuan Hu,

Ya-Che Lee

и другие.

Stem Cells Translational Medicine, Год журнала: 2024, Номер 13(8), С. 738 - 749

Опубликована: Июнь 12, 2024

Abstract Oncolytic adenoviruses have emerged as a promising therapeutic approach for cancer therapy. However, systemic delivery of the viruses to metastatic tumors remains major challenge. Mesenchymal stem cells (MSCs) possess tumor tropism property and can be used cellular vehicles delivering oncolytic sites. Since telomerase activity is found in ~90% human carcinomas, but undetected normal adult cells, reverse transcriptase gene (TERT) promoter exploited regulating replication adenoviruses. Here, we evaluated antitumor effects syngeneic murine MSCs loaded with luciferase-expressing, telomerase-dependent adenovirus Ad.GS2 (MSC-Ad.GS2) alone on MBT-2 bladder tumors. supported low degree replication, which could augmented by coculture or tumor-conditioned medium (TCM), suggesting that viral increased when MSC-Ad.GS2 migrates TCM enhanced Ad.GS2-infected MSCs. SDF-1 cell homing factor. Our results suggest SDF-1/STAT3/TERT signaling axis response microenvironment may contribute carried Notably, demonstrate potent efficacy systemically delivered pleural disseminated experimental metastasis models using intrapleural tail vein injection respectively. Treatment significantly reduced growth prolonged survival mice bearing expressed broad spectrum cancers, this strategy broadly applicable.

Язык: Английский

Процитировано

2